CombiMatrix Rebuffed, Hyseq Remains in Favor in Bid for Variangenics

genomeweb
360dx

CombiMatrix Rebuffed, Hyseq Remains in Favor in Bid for Variangenics

Jan 21, 2003

NEW YORK, Jan. 21 - Hyseq's bid to buy Variagenics is still a go after the attention of another suitor was rebuffed, Variagenics said today.

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

In Brief This Week: Thermo Fisher, Agilent, PerkinElmer, and More
People in the News: Mike Nolan, Erica Ramos, Cynthia Collins, More
BioGx Gets CE Marking for Six Meningitis, Antibiotic Resistance Tests
Pancreatic Cancer Analysis Unearths Outcome-Related Pathogenic BRCA Pathway Mutations
Epigenetic Variations Could Underlie Neurodevelopmental Disorders, Congenital Anomalies
Becton Dickinson Prices $685M Senior Notes Offering

The Scan

Last of the Northern White Rhinoceroses, Sequenced

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

DNA Phenotyping Allowed in Bavaria

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Thanks for the Stress, Dad

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

This Week in Science

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Main menu